2018
DOI: 10.1016/j.rmr.2017.10.017
|View full text |Cite
|
Sign up to set email alerts
|

Tolérance et efficacité en monde réel des inhibiteurs tyrosine-kinase (TKI) de l’EGFR chez les patients octogénaires atteints de cancer du poumon non à petites cellules (CPNPC) porteurs d’une mutation activatrice de l’EGFR. Étude OCTOMUT GFPC 07-15

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles